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igh-Dose Atorvastatin
n Acute Coronary and
erebrovascular Syndromes*
arl J. Lavie, MD, Richard V. Milani, MD
ew Orleans, Louisiana
ubstantial evidence has now supported vigorous lipid
ntervention in primary and secondary prevention of coro-
ary heart disease (CHD) (1,2), and the evidence support-
ng intensive lipid intervention with high-dose statins to
roduce clinical event reduction is especially powerful in the
etting of acute coronary syndrome (ACS) (3–5), including
he setting of percutaneous coronary intervention (PCI) (6),
nd acute cerebrovascular disease (7). Guidelines from the
ational Cholesterol Education Program (8), the American
eart Association/American College of Cardiology (9), and
he American Heart Association/American Stroke Associ-
tion (10) all support recommendations to lower low-
ensity lipoprotein cholesterol (LDL-C) to at least under
00 mg/dl, with recommendations to lower LDL-C 70
g/dl as a “therapeutic option.” Data to support LDL-C
70 mg/dl are especially applicable in patients following
CS (3–5).
See page 332
Following PCI, a recent substudy (6) of 2,868 patients
andomized to atorvastatin 80 mg or pravastatin 40 mg in
ROVE IT–TIMI 22 (Pravastatin or Atorvastatin Evalu-
tion and Infection Therapy–Thrombolysis In Myocardial
nfarction 22) trial demonstrated a 22% reduction (p 
.002) in the composite end point of major cardiovascular
vents as well as significant reductions in both target vessel
evascularization (TVR) (–39%, p  0.001) and non-TVR
–42%, p  0.017) in those treated with high-dose atorv-
statin. After adjustment for on-treatment LDL-C and
-reactive protein levels, the odds of reducing TVR with
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the Division of Cardiovascular Diseases, Ochsner Health System, New
rleans, Louisiana. Dr. Lavie is a speaker and consultant for Pfizer, GlaxoSmith
line, Bristol-Myers Squibb, Sanofi Aventis, Abbott, and Solvay. Dr. Milani is ae
peaker and consultant for Pfizer, AstraZeneca, Bristol-Myers Squibb, and Sanofi
ventis.torvastatin remained significant, suggesting that the reduc-
ion in TVR may be in part mediated by pleiotropic effects
ot accounted for by reductions in LDL-C and systemic
nflammation (6,11).
Following PCI, an increase in cardiac biomarkers has
een shown to occur in 5% to 30% of patients (12,13), and
his elevation of cardiac enzyme is indicative of cell death
nd a high risk of periprocedural mortality (14). In fact, we
ecently demonstrated that even borderline increases in
roponin following elective PCI predicted a higher mortality
14). Compelling data suggest that the statins may reduce
he rate of periprocedural myocardial infarction (MI)
12,13,15).
Briguori (13) assessed the value of a single 80 mg loading
ose of atorvastatin the day before elective PCI in 668
tatin-naïve patients. They reported a 44% reduction (p 
.01) in periprocedural MI in the atorvastatin-treated pa-
ients, with significant reductions also in the median crea-
ine kinase-myocardial band isoenzyme (p  0.01) and the
requency of cardiac troponin I elevation 3 the upper
imit of normal. In an accompanying editorial, Tsimikas
15) reviewed 6 studies, including 2 in ACS (16,17), of over
,000 PCI patients (4 studies with atorvastatin [3 using 80
g and 1 using 40 mg] (13,17–19), 1 with rosuvastatin 40
g (16), and the other using various statins), demonstrating
tatistically significant reductions in periprocedural MI us-
ng statin therapy. Tsimikas suggested that high doses of a
otent statin should be given similar priority as aspirin and
lopidogrel prior to patients undergoing PCI.
In this issue of JACC: Cardiovascular Interventions, Kim
t al. (20) assessed the efficacy of high-dose atorvastatin (80
g) versus low-dose atorvastatin (10 mg) in 171 ACS
atients with ST-segment elevation MI. This was similar to
he regimen used in the large-scale TNT (Treatment to
ew Targets) trial (21), which demonstrated the efficacy of
igh-dose (80 mg) atorvastatin versus low-dose (10 mg)
torvastatin in mostly stable patients with established CHD.
lthough the lipid arms in these 2 trials were similar, the
ecent PCI in ST-segment elevation MI trial was relatively
mall with only 30-day follow-up, whereas TNT random-
zed over 10,000 patients followed for 5 years. Unfortu-
ately, despite the fact that 80 mg atorvastatin was associ-
ted with a 46% reduction in the primary end point (death,
onfatal MI, and TVR), the study was not nearly powered
nough to assess this end point, because these events
ccurred in only 9 patients in the low-dose atorvastatin
roup (compared with 5 events in the high-dose group, p 
.26). Also, as the investigators mentioned, serial measure-
ent of cardiac enzymes were not available for all patients,
nd they were unable to calculate enzymatic infarct size
sing creatine kinase-myocardial band. Nevertheless, imme-
iate high-dose statin loading before PCI showed beneficial
ffects on myocardial perfusion, including significant reduc-
t
t
i
s
s
p
a
c
P
p
s
s
c
s
w
a
l
h
d
a
b
e
m
5
P
d
p
e
a
(
4
K
8
e
P
d
a
h
e
a
t
o
i
p
T
l
c
f
e
n
R
H
7
R
1
1
1
1
1
1
1
1
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 3 , 2 0 1 0 Lavie and Milani
MA R C H 2 0 1 0 : 3 4 0 – 2 Editorial Comment
341ions in the corrected Thrombolysis In Myocardial Infarc-
ion (TIMI) flow grade count (p  0.01), as well as
ncreases in myocardial blush grade (p  0.02) and ST-
egment resolution at 90 min after PCI (p  0.01), all
uggesting an improvement in microvascular myocardial
erfusion with high-dose (80 mg) versus low-dose (10 mg)
torvastatin in ST-segment elevation MI.
With the current level of knowledge, how should clini-
ians treat patients with CHD, including those undergoing
CI electively or in the setting of ACS? In our opinion, all
atients should be treated with a high dose of a potent
tatin, which should be started as outpatients or, in the
etting of ACS, as soon as possible on hospital arrival and
ertainly before PCI. High-dose (80 mg) simvastatin
howed some benefit during 2-year follow-up compared
ith low-dose (20 mg) simvastatin following ACS (5), but
s we have recently reviewed elsewhere (1,2,22), although
ower doses of simvastatin are generally well-tolerated this
igh dose of simvastatin (80 mg) has perhaps the most
rug-to-drug interactions and the greatest propensity
mong the statins for myopathy/rhabdomyolysis, and we
elieve that this dose (80 mg) should be used with consid-
rable caution. Rosuvastatin 40 mg, which is probably the
ost potent statin, was recently associated with a 40% to
0% reduction in periprocedural MI in 445 patients with
CI in ACS (16), and rosuvastatin 20 mg recently produced
ramatic benefits in primary CHD prevention (22). At
resent, however, 80 mg atorvastatin is the dose with proven
fficacy and safety in 2 large-scale ACS trials (3,4), as well
s the large PCI substudy (6), 2 large secondary CHD trials
21,23), a large acute cerebrovascular trial (7), and in at least
trials before PCI (12,17,18,20), including in the report by
im et al. (20) in the present issue. Therefore, atorvastatin
0 mg probably has the most compelling evidence, with
stablished efficacy and safety in ACS, before and following
CI, as well as in stable CHD. Further trials will likely
etermine if rosuvastatin’s greater potency translates to
dditional clinical benefits in ACS as well as in other
igh-risk patients.
Future studies are needed to determine if doses of statins
ven higher than standard lipid-lowering doses will result in
dditional benefit. As suggested by Tsimikas (15), we agree
hat based on the current data, a rationale for further testing
f higher anti-inflammatory doses in well-designed studies
s present, as well as doses with other potentially important
leiotropic effects, as suggested by the recent PROVE IT
IMI 22 substudy (6). Finally, there is evidence that high
evels of triglycerides and non-high-density lipoprotein
holesterol predicts prognosis following ACS (24). There-
ore, as in stable CHD, studies of lipid agents with greater
ffects on the triglycerides/high-density lipoprotein axis are
eeded following ACS and in the PCI patient (25,26).eprint requests and correspondence: Dr. Carl J. Lavie, Ochsner
ealth System, 1514 Jefferson Highway, New Orleans, Louisiana
0121. E-mail: clavie@ochsner.org.
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